Enrico Aitini

4.5k total citations · 1 hit paper
83 papers, 2.8k citations indexed

About

Enrico Aitini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Enrico Aitini has authored 83 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 15 papers in Cancer Research. Recurrent topics in Enrico Aitini's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (13 papers). Enrico Aitini is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (14 papers) and Lung Cancer Treatments and Mutations (13 papers). Enrico Aitini collaborates with scholars based in Italy, United States and Germany. Enrico Aitini's co-authors include Roberto Labianca, Alberto Zaniboni, Julien Taı̈eb, Céline Lepère, Aimery de Gramont, Christophe Louvet, Michel Ducreux, Pascal Hammel, Maria Giulia Zampino and Thierry André and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Enrico Aitini

82 papers receiving 2.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial

2005 760 citations Christophe Louvet, Roberto Labianca et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Enrico Aitini Italy	25	2.0k	1.0k	601	577	488	83	2.8k
Carlo Carnaghi Italy	29	2.0k 1.0×	849 0.8×	681 1.1×	523 0.9×	747 1.5×	93	3.3k
Giacomo Cartenì Italy	27	1.7k 0.9×	1.4k 1.4×	864 1.4×	521 0.9×	282 0.6×	110	3.2k
Gabriele Luppi Italy	28	3.4k 1.7×	1.3k 1.3×	1.7k 2.8×	398 0.7×	794 1.6×	105	4.3k
Luigi Manzione Italy	29	2.4k 1.2×	1.3k 1.2×	637 1.1×	394 0.7×	186 0.4×	88	3.4k
Jung Yong Hong South Korea	25	1.2k 0.6×	605 0.6×	407 0.7×	353 0.6×	243 0.5×	194	2.3k
Feng‐Hua Wang China	31	1.5k 0.8×	861 0.8×	637 1.1×	822 1.4×	256 0.5×	126	2.9k
Thomas A. Abrams United States	25	1.4k 0.7×	668 0.6×	655 1.1×	354 0.6×	306 0.6×	84	2.4k
Maria Giulia Zampino Italy	23	1.7k 0.9×	808 0.8×	625 1.0×	467 0.8×	325 0.7×	95	2.5k
Kazuhiro Sakamoto Japan	26	1.4k 0.7×	1.1k 1.0×	1.2k 1.9×	412 0.7×	294 0.6×	325	3.0k
Matias Riihimäki Sweden	12	1.4k 0.7×	821 0.8×	460 0.8×	295 0.5×	378 0.8×	12	2.2k

Countries citing papers authored by Enrico Aitini

Since Specialization

Citations

This map shows the geographic impact of Enrico Aitini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Enrico Aitini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Enrico Aitini more than expected).

Fields of papers citing papers by Enrico Aitini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Enrico Aitini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Enrico Aitini. The network helps show where Enrico Aitini may publish in the future.

Co-authorship network of co-authors of Enrico Aitini

This figure shows the co-authorship network connecting the top 25 collaborators of Enrico Aitini. A scholar is included among the top collaborators of Enrico Aitini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Enrico Aitini. Enrico Aitini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cascinu, Stefano, Rossana Berardi, Alberto F. Sobrero, et al.. (2013). Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Digestive and Liver Disease. 46(2). 182–186. 41 indexed citations

Zaniboni, Alberto, Enrico Aitini, Sandro Barni, et al.. (2012). FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Cancer Chemotherapy and Pharmacology. 69(6). 1641–1645. 65 indexed citations

Tan, E.H., Janusz Rolski, Tomasz Grodzki, et al.. (2009). Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology. 20(7). 1249–1256. 56 indexed citations

Galli, Luca, Andrea Fontana, C. Galli, et al.. (2007). Phase II study of sequential chemotherapy with docetaxel–estramustine followed by mitoxantrone–prednisone in patients with advanced hormone-refractory prostate cancer. British Journal of Cancer. 97(12). 1613–1617. 4 indexed citations

Mastro, Lucia Del, Béatrice Dozin, Enrico Aitini, et al.. (2007). Timing of adjuvant chemotherapy and tamoxifen in women with breast cancer: findings from two consecutive trials of Gruppo Oncologico Nord-Ovest–Mammella Intergruppo (GONO-MIG) Group. Annals of Oncology. 19(2). 299–307. 12 indexed citations

Cascinu, Stefano, Roberto Labianca, Carlo Barone, et al.. (2007). Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. JNCI Journal of the National Cancer Institute. 99(8). 601–607. 71 indexed citations

Bartolomeo, Maria Di, Roberto Buzzoni, Luigi Mariani, et al.. (2006). Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma. Oncology. 71(5-6). 341–346. 11 indexed citations

Bidoli, Paolo, Nicoletta Zilembo, Diego Cortinovis, et al.. (2006). Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Annals of Oncology. 18(3). 461–467. 28 indexed citations

Venturini, Marco, Lucia Del Mastro, Enrico Aitini, et al.. (2005). Dose-Dense Adjuvant Chemotherapy in Early Breast Cancer Patients: Results From a Randomized Trial. JNCI Journal of the National Cancer Institute. 97(23). 1724–1733. 107 indexed citations

10.

Louvet, Christophe, Roberto Labianca, Pascal Hammel, et al.. (2005). Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. Journal of Clinical Oncology. 23(15). 3509–3516. 760 indexed citations breakdown →

11.

Aitini, Enrico, Carla Rabbi, Andrea Mambrini, et al.. (2001). Epirubicin, Cisplatin and Continuous Infusion 5-Fluorouracil (ECF) in Locally Advanced or Metastatic Gastric Cancer: A Single Institution Experience. Tumori Journal. 87(1). 20–24. 3 indexed citations

12.

Costa, Paolo, Roberto Luzzati, A. Nicolato, et al.. (1998). Cryptococcal Meningitis and Intracranial Tuberculoma in a Patient with Waldenstrom's Macroglobulinemia Treated with Fludarabine. Leukemia & lymphoma. 28(5-6). 617–620. 19 indexed citations

13.

Cantore, Maurizio, G. Fiorentini, Claudio Bassi, et al.. (1997). Intra-Arterial Chemotherapy for Stage-lll/IV Pancreatic Cancer. Digestive Surgery. 14(2). 113–118. 9 indexed citations

14.

Leo, Angelo Di, Emilio Bajetta, Roberto Buzzoni, et al.. (1995). Epirubicin Plus Medroxyprogesterone as Second-Line Treatment of Advanced Prostatic Cancer. American Journal of Clinical Oncology. 18(3). 239–244. 4 indexed citations

15.

Zinzani, Pier Luigi, Maurizio Martelli, Sergio Storti, et al.. (1995). Phase III Comparative Trial Uisng CHOP vs CIOP in the Treatment of Advanced Intermediate-Grade Non-Hodgkin's Lymphoma. Leukemia & lymphoma. 19(3-4). 329–335. 24 indexed citations

16.

Toma, S., Raffaella Palumbo, Marco Vincenti, et al.. (1994). Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma. Annals of Oncology. 5(5). 463–465. 32 indexed citations

17.

Bajetta, Emilio, Nicoletta Zilembo, Maria Di Bartolomeo, et al.. (1993). Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer. 72(10). 3099–3105. 107 indexed citations

18.

Cavazzini, Giovanna, Maurizio Cantore, Enrico Aitini, et al.. (1993). Breast Metastasis from Gastric Signet Ring Cell Carcinoma, Mimicking Inflammatory Carcinoma. A Case Report. Tumori Journal. 79(6). 450–453. 21 indexed citations

19.

Cantore, Maurizio, et al.. (1991). [Lymphoma of the bladder. Description of 2 cases and review of the literature].. PubMed. 82(6). 328–30. 1 indexed citations

20.

Zinzani, Pier Luigi, Patrizio Mazza, Filíppo Gherlinzoni, et al.. (1990). Ceop Regimen in the Treatment of Advanced Low-Grade Non-Hodgkin's Lymphomas: Preliminary Report. Tumori Journal. 76(6). 533–536. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact